Biotechnology News and Research

RSS

NEJM publishes results from Teva's laquinimod Phase III study on RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced the publication of results from the laquinimod Phase III ALLEGRO study in the March 15 issue of The New England Journal of Medicine.

16 Mar 2012

Merck announces collaboration to create Calibr for early-stage translational research

Merck, known outside the United States and Canada as MSD, today announced a collaboration to create the California Institute for Biomedical Research (Calibr), an independent, not-for-profit organization (501c3) established to accelerate the translation of basic biomedical research into innovative, new medicines to treat disease.

16 Mar 2012

China Pharma revenue increases 9% to $81.2M for full year 2011

China Pharma Holdings, Inc., a fully-integrated specialty pharmaceuticals company in China, today announced financial results for the year ended December 31, 2011.

15 Mar 2012

Study identifies 190 proteins crucial to the functions of key immune sensors

In a healthy immune system, invading pathogens trigger a cascade of alerts and responses to fight off the infection. Sensors called toll-like receptors, or TLRs, act as one of the first lines of defense. Two of these sensors, known as TLR7 and TLR9, specifically recognize and respond to microbial RNA and DNA, respectively. But what determines how these TLRs get where they need to be and sound the alarm for pathogen infection?

15 Mar 2012

Researchers observe membrane repair in real-time in a living organism

Every cell is enclosed by a thin double layer of lipids that separates the distinct internal environment of the cell from the extracellular space. Damage to this lipid bilayer, also referred to as plasma membrane, disturbs the cellular functions and may lead to the death of the cell. For example, downhill walking tears many little holes into the plasma membranes of the muscle cells in our legs.

15 Mar 2012

Cadherin-23 might play a role in earliest stages of breast cancer metastasis

Rensselaer Polytechnic Institute Biologist Lee Ligon has found a previously unknown connection between breast cancer tumor cells and the surrounding healthy tissue. The results provide new information on the earliest stages of breast cancer metastasis.

15 Mar 2012

Teva commences commercial launch of Escitalopram Oxalate Tablets

Teva Pharmaceutical Industries Ltd. announced today that it has commenced commercial launch of Escitalopram Oxalate Tablets, the Company's generic version of Forest Laboratories' depression and generalized anxiety disorder treatment, Lexapro Tablets.

15 Mar 2012

Nuvilex discusses Cell-in-a-Box technology used for pancreatic cancer clinical trial

Nuvilex, Inc., an emerging biotechnology provider of cell and gene therapy solutions, discussed today the proprietary Cell-in-a-Box technology, being acquired from SG Austria, that was used for the pancreatic cancer clinical trial and may have an effect on downstream micro metastatic disease.

14 Mar 2012

Scientists gain insight into why lithium salts are effective at treating bipolar disorder

Scientists have gained insight into why lithium salts are effective at treating bipolar disorder in what could lead to more targeted therapies with fewer side-effects.

14 Mar 2012

MRI perfusion imaging can help determine brain tumor progression

Gliomas, the most common malignant brain tumors in adults, can be difficult to treat because of their aggressive and invasive nature. In treating patients with gliomas, it is increasingly important that doctors be able to detect tumor changes early when there's a better chance for recovery.

14 Mar 2012

New research could make it easier to grow health-promoting blood oranges

For the red pigmentation to develop, blood oranges normally require a period of cold as they ripen. The only place to reliably grow them on a commercial scale is in the Sicilian area of Italy around Mount Etna. Here, the combination of sun and cold/sunny days and warm nights provides ideal growing conditions.

14 Mar 2012

Biomedical research advances through new Australian Institute

The Institute of Biomedical Engineering and Technology (BMET) will be officially opened this evening at the University of Sydney, and will significantly advance this highly multidisciplinary research for life sciences and medicine.

14 Mar 2012

Bend Research announces licensing agreement with Affinium

Bend Research Inc., a leading independent drug-formulation development and manufacturing company, today announced a licensing agreement with Affinium Pharmaceuticals, Ltd.

13 Mar 2012

HemaQuest closes $13 million extension of Series B financing

HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that it has closed a $13 million extension of their Series B financing.

12 Mar 2012

Allon advances into second phase of work in preclinical PD model

Allon Therapeutics Inc. announced today the completion of its first phase of work in a preclinical Parkinson's disease model and advancement into the second phase of work. Both phases are funded by The Michael J. Fox Foundation for Parkinson's Research and carried out by Prof. Marie-Francoise Chesselet's lab at the University of California Los Angeles.

12 Mar 2012

ShangPharma fourth quarter net revenues increase 19.0% to $30.5 million

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its unaudited financial results for the fourth quarter and the fiscal year ended December 31, 2011.

12 Mar 2012

Salt resistant wheat developed using genomics

Matthew Gilliham, of the University of Adelaide, said the new variety of durum wheat would be made freely available to publicly funded breeding programs overseas. Field trials in Moree and at other sites across southern Australia have shown that the new variety has a grain yield in salty soil of up to 25 per cent higher than that of the standard variety.

12 Mar 2012

Ultragenyx completes UX001 Phase 1 study on hereditary inclusion body myopathy

Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the Phase 1 study of UX001 for hereditary inclusion body myopathy (HIBM) has been completed.

9 Mar 2012

3SBio fourth quarter total net revenues increase 38.2% to RMB139.9M

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced its unaudited financial results for the fourth quarter and full year ended December 31, 2011.

9 Mar 2012